ThinkEquity Upgrades Anadys Pharma (ANDS) to Buy
More News related to ANDS
- Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
- Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
- Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
More News related to Upgrades
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
- Santarus (SNTS) Jumps Ahead of Expected News
- Hemispherx Biopharma (HEB) Receives Letter for Ampligen From US FDA; FDA Cannot Approve Application in Present Form
- Hemispherx (HEB) Falls 30% as FDA Recommends Another Ampligen Study, Says Can't Approve Application in Present Form
ThinkEquity upgrades Anadys Pharma (Nasdaq: ANDS) from Accumulate to Buy with a $6 price target.
For more analyst ratings on ANDS click here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
